Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Teva generic approved

Jan. 31, 1997

CP-0840: Dual-action bradykinin antagonist/mu-opioid agonist from Cortech

Jan. 31, 1997

New MMP inhibitors reported by Warner-Lambert

Jan. 31, 1997

Potent NK1 antagonist reported by Servier

Jan. 30, 1997

Meperidine generic approved

Jan. 30, 1997

Candidate compound identified in Pharmacopeia/Berlex collaboration

Jan. 30, 1997

Clinical trials to begin on novel antidepressant from Korean company

Jan. 30, 1997

Schering Canada and University of Toronto collaborate on Alzheimer research

Jan. 30, 1997

Pilot trial of folic acid in stroke patients

Jan. 30, 1997

Cortex claims AMPA receptor modulators for CNS disorders

Jan. 30, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...